Dr. Ranee Mehra examines the use of immune checkpoint inhibitors in two patients with NSCLC. The goal of this activity is to improve clinicians' ability in managing patients with metastatic non-small cell lung cancer (mNSCLC) on immune checkpoint inhibitors (ICIs).
The presented cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.
This activity is intended for oncologists, pulmonologists, and pathologists.
Learning Objectives:
- Have increased knowledge regarding the
- Clinical trial data on the use of ICIs in patients with mNSCLC whose tumor does not contain an actionable mutation
- Have greater competence related to
- Identifying the necessary immunotherapeutic biomarkers to help guide first-line treatment decisions in patients with mNSCLC without actionable mutations
- Choosing the most appropriate first-line ICI regimen for a patient with mNSCLC without actionable mutations
- Management of adverse events in patients receiving front-line therapy for mNSCLC without actionable mutations
Approximate Time to Complete: 60 minutes
Credit Available: April 20, 2021 - April 20, 2022
Developed through a partnership between SITC and Medscape.
 |
|
Additional Resources for Clinicans from SITC:
"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)